Sahar Eljack

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 6

Top Topics

Breast Cancer Cells

Hyaluronic Acid

Iron Oxide Nanoparticles

Top Venues

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Sahar Eljack, Stephanie David, Igor Chourpa, Areeg Faggad, Emilie Allard-Vannier
Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Sahar Eljack, Stephanie David, Igor Chourpa, Areeg Faggad, Emilie Allard-Vannier
Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Sahar Eljack, Emilie Allard-Vannier, Yoann Misericordia, Katel Hervé-Aubert, Nicolas Aubrey, Igor Chourpa, Areeg Faggad, Stephanie David
Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells. Pharmaceutics 14 (11) (2022)
Sahar Eljack, Stephanie David, Igor Chourpa, Areeg Faggad, Emilie Allard-Vannier
Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Sahar Eljack, Stephanie David, Igor Chourpa, Areeg Faggad, Emilie Allard-Vannier
Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)
Sahar Eljack, Stephanie David, Igor Chourpa, Areeg Faggad, Emilie Allard-Vannier
Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment. Pharmaceuticals (Basel, Switzerland) 15 (12) (2022)